This post is a brilliant summary. Nominated.What is Rfreq and Rseq?
(clip)
Some brave moderator should spare us further punishment and close the thread.
This post is a brilliant summary. Nominated.What is Rfreq and Rseq?
(clip)
Shalamar, you should take a university-entrance exam in England, you would pass with flying colors.Shalamar said:Good thing then that Evolution doesn't really talk about Survival of the Fittest.
rocketdodger said:What is Rfreq and Rseq?
rocketdodger said:(clip)kjkent1 said:This post is a brilliant summary. Nominated.
You find the mathematical and empirical evidence of how the mutation and selection sorting/optimization process actually works punishing? I thought it was only annoying. I pray for God’s forgiveness that I enjoy the thought that showing how the mutation and selection sorting/optimization process is punishing for a legal beagle. Well, that’s a legal beagle whose only argument for his theory is to censor those who don’t believe his irrational and illogical theory.kjkent1 said:Some brave moderator should spare us further punishment and close the thread.
It didn’t take very long for the English Empire to evaporate...
Show us your mathematics.Shalamar said:And oh? Kleinman? Survival of the Fittest is a largely Darwinian term. The ToE shows that it is not just the fittest that survive. Just the 'Fit enough'. Or not the least fit.
Show us your mathematics
Show us your mathematics.
You've stated that population size doesn't matter in the progress of evolution. I'm not trying to straw man, that's just what I recall. This seems to me to be quite unintuitive. If, for example, there's a one in a billion chance of a specific adaptive mutation happening in a bacterium in a day, the a population of a billion would be expected to achieve this mutation, on the everage, once a day. Double the population, and you expect to see a similar mutation twice a day. Seems obvious to me. The vast populations even in something like a serious HIV infection would seem to be beyond the scope of a limited program like Ev.
So please convince me of your claim that population size has no bearing on the progress of evolution. I'm willing to listen.
Kleinman said:Show us your mathematicsHenners said:Show us your carpet.
Kleinman said:Henners said:
Come on, you've only every done one thing around here, and we know what it is.
You are correct; I’m pulling the rug from under your theory. And that rug is woven from mathematical and empirical evidence. I hope you find that annoying but not too punishing unless you are a legal beagle.
Mr Scott said:I'll repeat this essential question you ignored, Dr. Kleinman. Perhaps there's a problem with your browser:Mr Scott quoting said:You've stated that population size doesn't matter in the progress of evolution. I'm not trying to straw man, that's just what I recall. This seems to me to be quite unintuitive. If, for example, there's a one in a billion chance of a specific adaptive mutation happening in a bacterium in a day, the a population of a billion would be expected to achieve this mutation, on the everage, once a day. Double the population, and you expect to see a similar mutation twice a day. Seems obvious to me. The vast populations even in something like a serious HIV infection would seem to be beyond the scope of a limited program like Ev.
Mr Scott said:Mr Scott quoting said:
So please convince me of your claim that population size has no bearing on the progress of evolution. I'm willing to listen.
Oh, you want me to explain to you what Rfreq and Rseq are? Why don’t you read Dr Schneider’s web site.Shalamar said:Kleinman, Why don't you address Rocketdodgers points on ev?
You are as clear as a London fog, fitting for someone who believes in a theory that only exists in a fog. But don’t worry, we have Dr Schneider’s peer reviewed and published mathematical model of random point mutations and natural selection and hundreds of real examples of mutation and selection to clear away that fog.Henners said:Perhaps I didn't make myself clear.
You are as clear as a London fog, fitting for someone who believes in a theory that only exists in a fog.
If you were an evolutionist with any competence in the mathematics of mutation and selection sorting/optimization process, you could judge but since evolutionists get their degrees from Mathishard University, it makes it quite difficult for you to judge.Henners said:If you like to screw stuff made of mathematics, well, who am I to judge?
Kleinman said:You are as clear as a London fog, fitting for someone who believes in a theory that only exists in a fog.Henners said:The theory only exists in a fog?
That correct, rubbish can exist in fog, don’t you remember the black fog in London?Kleinman said:Henners said:Rubbish.
Wait a minute; are you discrediting the picture I posted of a Wookie? Don’t you know that joobz, the Wookie Weatherman has shown that the weather evolves Wookies, it was probably in a London black fog. Now Henners, since you like my pictures so much, let me post a word picture which shows how the mutation and selection sorting/optimization process actually works and it doesn’t work anything like you evolutionists allege. Bow wow.Henners said:I've seen all the pictures you posted, you disgusting little pup.
Hey kjkent1, this word picture is for you to. You had better contact these authors and tell them that HBV does frame shifts and therefore combination therapy will not work.Combination Chemotherapy for Hepatitis B Virus: The Path Forward? said:Hepatitis B virus (HBV) was identified as a cause of viral hepatitis more than 30 years ago and hepatitis B vaccines have been available for almost 20 years, but HBV infection continues to be a global health problem, responsible for about 1.2 million deaths annually. By the end of this year, almost 400 million people - about 5% of the world's population and more than ten times the number infected with human immunodeficiency virus (HIV) - will be infected with HBV. Chemotherapy remains the only treatment option for controlling chronic HBV infection once acquired, but none of the many different chemotherapeutic strategies used in the past has proven consistently successful. Prospects for successful treatment of HBV have improved dramatically during the past decade due to the development of new, well tolerated and efficacious anti-HBV drugs, and to advances in our understanding of HBV replication and pathogenesis. The newer anti-HBV drugs are capable of reducing viral loads very rapidly, but the initial response is invariably followed by very much slower elimination of residual virus. As more effective anti-HBV drugs become available, the emergence of drug resistance during the slower phase of HBV elimination will probably become the most significant obstacle in the way of eventual control of HBV infection. Experience with HIV indicates that combination chemotherapy may suppress or eliminate drug resistance and methods for pre-clinical and clinical assessment of anti-HBV drug combinations are being developed. Basic research into mechanisms of drug action and interaction should assist in the design and optimisation of combination chemotherapy for HBV infection, for which additional new anti-HBV drugs will undoubtedly be required in future.
If you were an evolutionist with any competence in the mathematics of mutation and selection sorting/optimization process, you could judge but since evolutionists get their degrees from Mathishard University, it makes it quite difficult for you to judge.
What’s the matter Henners, do you have your evolutionary shorts in a mathematical wedgie?Henners said:"...excessive seeking for attention, criticism of others, overly dutiful obedience, and worry."
AndDRUG COMBINATIONS AND THE CONTROL OF RESISTANCE IN PLASMODIUM FALCIPARUM said:The rationale for combining drugs with independent modes of action to prevent the emergence of resistance was developed first in antituberculous chemotherapy. It has subsequently been adopted in the treatment of cancer and, more recently, AIDS. These infections are now never treated with a single drug. The same should apply to the treatment of malaria. The principle is simple. Resistance arises from one or more mutations. These will be selected when exposed to concentrations of antimalarial drug which kill susceptible parasites but not those with the mutation(s). When two unrelated drugs are used together, a parasite with mutations conferring resistance to one drug will be killed by the other drug, and vice versa. The chance that a mutant will emerge that is simultaneously resistant to both the drugs is the product of the individual mutation frequencies, and will be many orders of magnitude lower than that for the drugs individually. Thus, compared with sequential use of single drugs (current policy), combinations will considerably retard the development of resistance. Artemisinin and its derivatives (artesunate, artemether, dihydroartemisinin) are the most potent and rapidly acting of antimalarials, reducing the infecting parasite biomass by approximately 10,000-fold per asexual (two day) life cycle compared to 100 to 1,000-fold for other antimalarial drugs. They are remarkably well tolerated and no significant resistance has been reported either in clinical isolates or in laboratory experiments. Combinations of artemisinin, or one of its derivatives, and mefloquine or lumefantrine (benflumetol) have proved highly effective even against multi-drug resistant P. falciparum. On the North-Western border of Thailand, which harbours the most resistant P. falciparum in the world, the use of combination chemotherapy has halted the progression of mefloquine resistance. This is attributed to two factors. First, combinations ensure high cure rates because the residuum of parasites remaining after treatment with an artemisinin derivative for three or more days is exposed to maximum concentrations of the more slowly eliminated mefloquine. This residuum (a maximum of 105 parasites or 0.000001% of the asexual parasites present initially) is all that is exposed to mefloquine alone, thus the selective pressure for the emergence of mutants with reduced mefloquine sensitivity is lessened considerably. Second, the artemisinin derivatives reduce gametocyte carriage by approximately 90%. Recrudescent (i.e. resistant) infections are associated with increased gametocyte carriage rates which provide a powerful selection pressure to the spread of resistance. This is prevented by the artemisinin derivatives. Combination therapy makes therapeutic sense, and there are good arguments for combining an artemisinin derivative with all antimalarial drugs.
Now you all have a good weekend and I’ll be back next week to annoy you with more citations which show how the mutation and selection sorting/optimization process actually works. If you are a legal beagle it does a little more than annoy you, God forgive me for enjoying that.CLINICAL DATA FROM THAILAND ON DECREASED RESISTANCE AND TRANSMISSION WITH DRUG COMBINATIONS said:The combination of artesunate and mefloquine is now the standard treatment for uncomplicated falciparum malaria in the displaced populations living on the Thai-Burmese border. The use of the combination was made necessary because P. falciparum had developed high-grade resistance to all antimalarials, including mefloquine and halofantrine. Since 1994, all patients with uncomplicated falciparum infections have received artesunate (4 mg/kg/day for 3 days) combined with mefloquine (25 mg/kg) as first-line therapy. The in vivo efficacy, prospectively monitored in over 3000 patients, has remained high and stable (95%). This stabilisation of mefloquine efficacy for the 4th consecutive year, following the rapid decline that we witnessed between 1986 and 1994, was confirmed by in vitro sensitivity monitoring. This coincides with a rapid decline in the incidence of falciparum (but not vivax) malaria incidence in the populations where the combination is used, but not in the surrounding communities. Concomitantly, entomological surveillance indicates that the mosquito vector abundance remains unchanged but that only vivax (and not falciparum) sporozoites can be detected in the salivary glands of the anophelene captures. Clinical studies indicate that the rate of gametocyte carriage in the population increased with the decline in mefloquine efficacy when the drug was used alone. However, we described how artemisinin derivatives reduce the gametocyte carriage rate by 90% following treatment of an acute episode. The rapid effect (and elimination) of artesunate on sexual and asexual stages of the parasite reduces the selective drug pressure of the slowly eliminated mefloquine (i.e. artesunate protects mefloquine and vice versa), prevents the spread of resistant strains, and selectively reduces falciparum transmission. The same impact on transmissibility of falciparum malaria was observed with another highly effective combination: artemether-benflumetol. All patients with P. falciparum infection should be treated with a combination of drugs that includes an artemisinin derivative.
Math Forum @ Drexel said:y = 1/3 x + 4
Here are some of the variables in this functional relationship:Evolution of Biological Information said:Variations of the program could be used to investigate how population size, genome length, number of sites, size of recognition regions, mutation rate, selective pressure, overlapping sites and other factors affect the evolution. Another use of the program may include understanding the sources and effects of skewed genomic composition (4,7,30,31).
Well this is a little change of pace. No evolutionists have responded this weekend. Have I bored you?
Or have I convinced you with the empirical evidence of how the mutation and selection sorting/optimization process actually works? Have you read Dr Schneider’s web site and learned how mutation and selection works? Do you all understand Dr Schneider’s mathematics? I think I’ll change gears and stop posting empirical examples and show you how you to study the mathematics of mutation and selection sorting/optimization process. In order to study the mathematics of mutation and selection you need to understand two advanced topics of mathematics, analytic geometry and functional analysis. I’m going to assume that you evolutionists understand basic algebra and will start the discussion from this point. We’ll start with the basics on analytic geometry. Do you recall the following equation?